<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3633">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637906</url>
  </required_header>
  <id_info>
    <org_study_id>Bioarginina</org_study_id>
    <nct_id>NCT04637906</nct_id>
  </id_info>
  <brief_title>Short and Long-term Effects of Adding Oral L-arginine to Standard Therapy in Patients With COVID-19 (SARS-CoV-2)</brief_title>
  <official_title>Short and Long-term Effects of Adding Oral L-arginine to Standard Therapy in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Randomized, Parallel Group, Double-blind Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center study with a parallel group scheme, double-blind, randomized,&#xD;
      placebo-controlled, to evaluate whether the addition to the investigator's hospital standard&#xD;
      therapy of two vials of Bioarginina® per day in subjects with SARS-CoV-2 is useful for&#xD;
      treatment of this pathology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary experiences conducted in patients affected by SARS-CoV-2 infection by adding the&#xD;
      daily oral administration of two vials of Bioarginina® to the standard therapy have shown&#xD;
      favorable effects on discharge times, on the recovery of the number of lymphocytes and on the&#xD;
      P \ F ratio between arterial pO2 and FiO2 breathed. In particular, for the latter parameter&#xD;
      there is almost a doubling of the recovery speed.&#xD;
&#xD;
      The investigators therefore, decided to undertake the present spontaneous, single-center&#xD;
      study with a parallel group scheme, double-blind randomized, placebo-controlled to evaluate&#xD;
      whether the addition to the standard therapy of two vials per day of Bioarginina® in subjects&#xD;
      of our hospital suffering from SARS-CoV-2 is useful for the treatment of this pathology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2020</start_date>
  <completion_date type="Anticipated">September 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 18, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of P / F normalization times</measure>
    <time_frame>60 days</time_frame>
    <description>Alveolar pressure of oxygen / inspiratory fraction of oxygen</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>L-arginine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bioarginina®, 2 orally administered vials per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 orally administered vials per day of Bioarginina® without L-arginine</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bioarginina®</intervention_name>
    <description>Food supplement based on 1,66 grams of L-arginine</description>
    <arm_group_label>L-arginine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age&gt; 18 years&#xD;
&#xD;
          -  Diagnosis of COVID 19, confirmed by RT-PCR on a nasopharyngeal swab&#xD;
&#xD;
          -  COVID 19 pneumonia with the following clinical characteristics: SpO2 in ambient air&#xD;
             &lt;93% and Alveolar pressure of oxygen / inspiratory fraction of oxygen (PaO2 / FiO2 - P&#xD;
             / F &lt;300 mmHg.&#xD;
&#xD;
          -  Lymphocytopenia defined as lymphocytes &lt;1500 / mcL or &lt;20% of white blood cells&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of intolerance to L-arginine&#xD;
&#xD;
          -  Severe chronic pulmonary disease&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Neutropenia due to neoplasms of the haematopoietic system or other organs with&#xD;
             invasion of the bone marrow&#xD;
&#xD;
          -  Use of immunosuppressive drugs or cytotoxic chemotherapies within the previous three&#xD;
             weeks&#xD;
&#xD;
          -  Refusal to give consent to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Fiorentino</last_name>
    <role>Principal Investigator</role>
    <affiliation>università degli studi della campania Luigi Vanvitelli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>barbara maglione</last_name>
    <phone>3343293357</phone>
    <phone_ext>3343293357</phone_ext>
    <email>bmaglione@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliera Specialistica Dei Colli</name>
      <address>
        <city>Napoli</city>
        <zip>80123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>barbara maglione</last_name>
      <phone>3343293357</phone>
      <email>bmaglione@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>giuseppe fiorentino</investigator_full_name>
    <investigator_title>PROFESSOR</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

